Solid Biosciences to Participate in Citi’s 18th Annual BioPharma Conference
31 Agosto 2023 - 7:00AM
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company
developing genetic medicines for neuromuscular and cardiac
diseases, today announced that Bo Cumbo, President and Chief
Executive Officer, will present at the Citi 18th Annual
BioPharma Conference on Thursday, September 7,
2023, at 9:40 AM ET.
A live webcast of the presentation will be
available on the Events page of the Investors section of the
Company website or by clicking here. A webcast replay will be
archived for 30 days on the Events page.
Institutional investors interested in meeting
with management during the conference may reach out to their Citi
representative.
About Solid Biosciences
Solid Biosciences is a life science company
focused on advancing a portfolio of neuromuscular and cardiac
programs, including SGT-003, a differentiated gene transfer
candidate for the treatment of Duchenne muscular dystrophy
(Duchenne), AVB-401 a gene therapy program for the treatment of
BAG3 mediated dilated cardiomyopathy, AVB-202-TT, a gene therapy
program for the treatment of Friedreich’s Ataxia, and additional
assets for the treatment of undisclosed fatal cardiac diseases.
Solid aims to be the center of excellence across a given disease
spectrum bringing together those with expertise in science,
technology, disease management, and care. Patient-focused and
founded by those directly impacted, Solid’s mandate is to improve
the daily lives of patients living with these devastating diseases.
For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:Leah
MonteiroVP, Investor Relations &
Communications617-821-4427lmonteiro@solidbio.com
Solid Biosciences (NASDAQ:SLDB)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Solid Biosciences (NASDAQ:SLDB)
Gráfica de Acción Histórica
De May 2023 a May 2024